Kura Oncology (KURA) Receivables (2024 - 2026)

Kura Oncology (KURA) has 3 years of Receivables data on file, last reported at $9.3 million in Q1 2026.

• On a quarterly basis, Receivables fell 80.82% year-over-year to $9.3 million in Q1 2026; TTM through Mar 2026 was $9.3 million, a 80.82% decrease from a year earlier, with the FY2025 full-year figure at $8.8 million, up 327.38% from the prior year.
• Receivables for Q1 2026 stood at $9.3 million, up from $8.8 million in the prior quarter.
• Over the last five years, Receivables for KURA reached as high as $48.7 million in Q1 2025 and fell as low as $2.1 million in Q4 2024.
• Historically, Receivables has averaged $18.2 million across 3 years, with a median of $9.1 million in 2025.
• Across the five-year window, Receivables jumped 327.38% in 2025 and slumped 80.82% in 2026, its largest moves.
• Year by year, Receivables stood at $2.1 million in 2024, then soared by 327.38% to $8.8 million in 2025, then climbed by 6.18% to $9.3 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $9.3 million in Q1 2026, $8.8 million in Q4 2025, and $35.9 million in Q3 2025.